China Decode: Why Unrest in Iran is a Problem for China - The Prof G Pod with Scott Galloway Recap
Podcast: The Prof G Pod with Scott Galloway
Published: 2026-01-13
Duration: 50 minutes
Guests: Michal Meidan
Summary
The episode examines how unrest in Iran, amidst Trump's intervention in Venezuela, threatens China's energy security and geopolitical stance. It also touches on China's growing obesity crisis and its economic implications.
What Happened
China is facing a complex geopolitical situation with ongoing protests in Iran and the US's intervention in Venezuela, two countries that together account for about 20% of China's oil imports. Michal Meidan from the Oxford Institute for Energy Studies discusses China's deep economic ties with Iran, highlighting China's role as Iran's largest trade partner, purchasing about 90% of its oil at discounted prices due to sanctions. China has also committed $25 billion in loans for Iran's infrastructure projects and a $400 billion investment deal over 25 years, underscoring its strategic interest in the region.
The conversation underscores China's strategy in Latin America, where it has economically displaced the US in 10 out of 12 countries. China's investments include military equipment sales and dual-use technologies, with Venezuela playing a key role as a major oil supplier, particularly to China's independent refiners known as 'Shandong teapots.' The US's control over Venezuelan oil sales presents a strategic challenge to China's interests.
China's economic influence extends beyond oil, with the country stockpiling oil to manage price volatility and reduce reliance on imports. This strategy is part of broader efforts to hedge against the US dollar by using the Chinese Yuan for trade invoicing and settlement in energy commodities. As the situation in Iran unfolds, these economic measures become crucial in maintaining China's energy security.
On the domestic front, China faces a rising obesity crisis, with more than half of its adult population overweight, a trend that could see 65% of adults affected by 2030. This has led to the emergence of 'fat prisons,' weight loss camps that aim to control this public health issue. Alongside these camps, China is also producing GLP-1 drugs, which are becoming more affordable and widely available as local manufacturers enter the market.
GLP-1 drugs, used for weight management, are priced between $385 and $685 in China, about half the cost in the US. Innovent Biologics is among the companies developing these drugs, with products like Mazdatide and UBT251 in the pipeline. The pharmaceutical landscape is further enriched by over 60 GLP-1 drug candidates in late-stage clinical trials, reflecting a booming sector focused on addressing obesity.
The episode also notes cultural shifts contributing to obesity, such as more people eating out and a sedentary corporate lifestyle. Predictions of a fitness boom in China could drive growth in the sports equipment and sportswear markets, as the country grapples with the dual challenges of health governance and commercial opportunities.
Key Insights
- China imports about 20% of its oil from Iran and Venezuela, making the unrest in these regions a significant concern for its energy security. China is Iran's largest trade partner, purchasing approximately 90% of its oil at discounted prices due to sanctions.
- China has committed $25 billion in loans for Iranian infrastructure and a $400 billion investment deal over 25 years, highlighting its strategic economic interests in the region. This deep economic involvement underscores China's reliance on Iranian oil amidst geopolitical tensions.
- China's strategy to manage energy security includes stockpiling oil to mitigate price volatility and using the Chinese Yuan for trade invoicing and settlement in energy commodities. This approach aims to reduce reliance on the US dollar and stabilize its energy imports.
- China faces a rising obesity crisis, with projections indicating 65% of adults could be overweight by 2030. In response, the country is producing GLP-1 drugs for weight management, priced between $385 and $685, which is about half the cost in the US, with over 60 drug candidates in late-stage clinical trials.